28th Apr 2011 07:00
28 April 2011
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Total Voting Rights and Issued Share Capital
Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces that the Company's share capital consists of 310,771,614 Ordinary 0.1p shares with voting rights attached (one vote per Ordinary share). The Company has no shares in Treasury therefore the total number of voting rights in Allergy Therapeutics is 310,771,614.
The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Allergy Therapeutics under the FSA's Disclosure and Transparency Rules.
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
www.allergytherapeutics.com | |
Nomura Code Securities | +44 (0) 207 776 1200 |
Juliet Thompson/ Clare Terlouw | |
Financial Dynamics | +44 (0) 207 831 3113 |
Ben Brewerton/ Susan Quigley |
Related Shares:
Allergy Thera.